Anebulo Pharmaceuticals, Inc. financial data

Symbol
ANEB on Nasdaq
Location
C/O Anebulo Pharmaceuticals, Inc., 1017 Ranch Road 620 South, Suite 107, Lakeway, TX
Fiscal year end
June 30
Latest financial report
10-Q - Q3 2025 - Nov 13, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Debt-to-equity 5.77 % -65.2%
Return On Equity -67.8 % +63.2%
Return On Assets -64.1 % +59.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 41.1M shares +58.4%
Common Stock, Shares, Outstanding 41.1M shares +58.4%
Entity Public Float 15.1M USD +59%
Common Stock, Value, Issued 41.1K USD +58.4%
Weighted Average Number of Shares Outstanding, Basic 41.1M shares +58.4%
Weighted Average Number of Shares Outstanding, Diluted 41.1M shares +58.4%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 3.8M USD +5.61%
General and Administrative Expense 5.28M USD +15.1%
Operating Income (Loss) -9.07M USD -10.9%
Nonoperating Income (Expense) 629K USD +146%
Net Income (Loss) Attributable to Parent -8.44M USD -6.57%
Earnings Per Share, Basic 0 USD/shares +26.7%
Earnings Per Share, Diluted 0 USD/shares +26.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 10.4M USD +637%
Assets, Current 10.5M USD +437%
Other Assets, Noncurrent 166K USD -67.2%
Assets 10.7M USD +334%
Accounts Payable, Current 608K USD +141%
Accrued Liabilities, Current 356K USD +12.4%
Liabilities 964K USD +69.3%
Retained Earnings (Accumulated Deficit) -76M USD -12.5%
Stockholders' Equity Attributable to Parent 9.74M USD +413%
Liabilities and Equity 10.7M USD +334%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.27M USD +24.7%
Common Stock, Shares Authorized 75M shares +50%
Common Stock, Shares, Issued 41.1M shares +58.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.27M USD +24.7%
Deferred Tax Assets, Valuation Allowance 7.98M USD +24.5%
Deferred Tax Assets, Gross 7.98M USD +24.5%
Deferred Tax Assets, Operating Loss Carryforwards 5.15M USD +37.7%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 2M shares 0%
Additional Paid in Capital 85.7M USD +23.4%
Preferred Stock, Shares Outstanding 0 shares
Interest Expense 17K USD -83%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%